Oslo, Norway, 28 August 2008 - Algeta ASA, the cancer therapeutics company, today announced the results from a phase II pain palliation clinical study in prostate cancer patients.
Pain palliation is an important quality of life benefit for metastatic prostate cancer patients. The study showed that even single doses of Alpharadin could produce clinical palliative benefit where the palliative effect increased with increasing dose. The trial also confirmed the safety of Alpharadin and shown its benign side-effect profile.
These results strengthen the total value proposition of Alpharadin as a product that can increase both survival and quality of life with very mild side effects in prostate cancer patients.